`
`New hope in advanced prostate cancer: Alberta, Saskatchewan and Ontario fund coverage for JEVTANA®
`
`New hope in advanced prostate cancer: Alberta,
`Saskatchewan and Ontario fund coverage for JEVTANA®
`(Cabazitaxel)
`
`
`
`
`
`
`
`
`
` English
`
`Therapy provides significant survival benefit in secondline metastatic hormonerefractory prostate cancer
`in combination with prednisone.
`
`LAVAL, QC, Oct. 4, 2012 /CNW Telbec/ Sanofi is pleased to announce that the provinces of Alberta, Saskatchewan
`and Ontario have listed JEVTANA® (cabazitaxel) on their respective provincial formulary so that it is now eligible for
`reimbursement for patients with advanced prostate cancer. JEVTANA®(cabazitaxel) is indicated as a second line
`
`treatment of castration resistant (hormone refractory) metastatic prostate cancer (mHRPC) in combination with
`prednisone in patients who have received prior treatment with a docetaxel containing regimen.
`
`"JEVTANA fills a critical treatment gap, since it is the novel treatment approved for patients with this stage of
`metastatic hormonerefractory prostate cancer. The ability to access JEVTANA and to know that Alberta,
`Saskatchewan and Ontario are funding the treatment is a major gain for men dealing with the disease and their
`families," said Dr. Stan Glezer, Vice President of Evidence, Value and Access. "Sanofi is strongly committed to
`bringing innovative therapies to the cancer community and to working in cooperation with the provincial health
`agencies to demonstrate the value of medicine for the patients and contribute to the sustainability of the healthcare
`system."
`
`The combination of JEVTANA® and prednisone is the first and only chemotherapy to have shown a significant
`survival benefit for men with mHRPC previously treated with a docetaxelcontaining regimen.
`
`Reimbursement for prescription drugs is not mandated by the Canada Health Act or any other federal legislation.
`Provincial governments independently establish reimbursement plans.
`
`"We trust other provinces will follow the lead of Alberta, Saskatchewan and Ontario and approve coverage of this
`treatment option," added Dr. Glezer. "JEVTANA is an important therapy addition for patients living with mHRPC and
`helps healthcare professionals in their efforts to treat those patients. Hopefully the availability of a drug like
`JEVTANA®(cabazitaxel) will signal the start of a new, more effective approach to help these patients access the
`
`treatment."
`
`"Access and availability in Alberta to new options such as JEVTANA®can provide patients with a better chance of
`
`survival when dealing with such a difficult illness," concluded Bob Shiell, Executive Director, Prostate
`Cancer Canada Network (PCCN) Calgary.
`About JEVTANA®
`JEVTANA® (cabazitaxel) is approved as a secondline treatment option for metastatic castration resistant (hormone
`refractory) prostate cancer (mCRPC). JEVTANA® is a chemotherapy compound used with the steroid medicine
`[i]
`prednisone or prednisolone to treat people with mCRPC previously treated with a docetaxelcontaining treatment
`regimen.
`[ii]
`
`Jevtana® is a registered trademark of Sanofi.
`About Prostate Cancer
`Worldwide, prostate cancer ranks third in cancer incidence and sixth in cancer mortality in men. In the U.S., prostate
`
`http://www.newswire.ca/newsreleases/newhopeinadvancedprostatecanceralbertasaskatchewanandontariofundcoverageforjevtanacabazitaxel510… 1/3
`
`AVENTIS EXHIBIT 2222
`Mylan v. Aventis IPR2016-00712
`
`
`
`New hope in advanced prostate cancer: Alberta, Saskatchewan and Ontario fund coverage for JEVTANA®
`12/22/2016
`cancer remains the second most common cause of cancer death among men after lung cancer. In Canada, one man
`in seven men will develop prostate cancer. It is the most frequently diagnosed cancer in men and its incidence has
`increased by 30 percent since 1988. While it is most commonly diagnosed after age 70, prostate cancer can also
`occur in men in their forties and fifties.
`For many patients with prostate cancer, their disease continues to progress
` [ii1]
`despite prior treatment including surgical and/or hormonal castration followed by chemotherapy. Metastatic prostate
`cancer indicates that the cancer has spread to the lymph nodes or other parts of the body, particularly the bones.
`Castration resistant/hormonerefractory prostate cancer means that the cancer has continued to grow despite the
`suppression of male hormones that fuel the growth of prostate cancer cells. An estimated 1020% of patients with
`prostate cancer are diagnosed when the cancer has already metastasized.
`About Sanofi
`Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused
`on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes
`solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new
`Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
`
`Sanofi companies in Canada include sanofiaventis Canada Inc. (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi
`Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health). Together they employ
`more than 1,700 people, mainly in the greater Montreal and Toronto areas. In 2011 Sanofi companies
`invested $151.7 million in R&D in Canada, creating jobs, business and opportunity throughout the country. For
`additional information, please visit http://www.sanofi.ca .
`
`_______________________
` "About Jevtana." Sanofiaventis Oncology. Available online: https://www.sanofi
`[i]
`aventisoncology.com/wps/portal/oncology/products/jevtana. Accessed 2/23/2011.
`
` "About Jevtana." Sanofiaventis Oncology. Available online: https://www.sanofi
`[ii]
`aventisoncology.com/wps/portal/oncology/products/jevtana. Accessed 2/23/2011.
`
` Prostate Cancer: Understand the Disease and its Treatment: Saad F, McCormack M; Annika Parance Publishing;
`[iii]
`2012, p. 25
`
`SOURCE: SANOFI
`
`For further information:
`MEDIA
`Caroline Martel
`Communications Consultant, Sanofi Canada
`5149566120
`caroline.martel@sanofi.com
`
`Organization Profile
`
`SANOFI
`
`http://www.newswire.ca/newsreleases/newhopeinadvancedprostatecanceralbertasaskatchewanandontariofundcoverageforjevtanacabazitaxel510… 2/3
`
`
`
`New hope in advanced prostate cancer: Alberta, Saskatchewan and Ontario fund coverage for JEVTANA®
`12/22/2016
`Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo® to Insulin Degludec in People With Type 1
`Diabetes
`
`Toujeo® Demonstrates a More Stable Profile and Lower Withinday Variability Compared to Insulin Degludec
`
`Sanofi's Toujeo® Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus® at All
`Levels of HbA1c control
`
`More on this organization
`
`CUSTOM PACKAGES
`Browse our custom packages or build your own to meet your unique communications needs.
`
`Start today.
`
`CNW MEMBERSHIP
`Fill out a CNW membership form or contact us at 1 (877) 2697890
`
`LEARN ABOUT CNW SERVICES
`Request more information about CNW products and services or call us at 1 (877) 2697890
`
`http://www.newswire.ca/newsreleases/newhopeinadvancedprostatecanceralbertasaskatchewanandontariofundcoverageforjevtanacabazitaxel510… 3/3